Black Diamond Therapeutics Financial Statements (BDTX)
|
|
|
|
Report date
|
|
|
24.03.2020 |
25.03.2021 |
17.03.2022 |
09.03.2023 |
12.03.2024 |
|
05.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
4.89 |
|
Operating Income, bln rub |
|
|
-8.90 |
-69.6 |
-126.9 |
-92.8 |
-86.5 |
|
-81.4 |
|
EBITDA, bln rub |
? |
|
-29.3 |
-66.7 |
-126.7 |
-92.3 |
-86.0 |
|
-78.4 |
|
Net profit, bln rub |
? |
|
-41.1 |
-65.5 |
-123.2 |
-84.5 |
-82.4 |
|
-73.1 |
|
|
OCF, bln rub |
? |
|
-24.7 |
-52.1 |
-100.1 |
-85.1 |
-66.7 |
|
-61.2 |
|
CAPEX, bln rub |
? |
|
0.021 |
0.142 |
2.71 |
0.192 |
0.033 |
|
29.5 |
|
FCF, bln rub |
? |
|
-24.7 |
-52.3 |
-102.9 |
-85.3 |
-66.8 |
|
-46.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
29.3 |
69.6 |
126.9 |
92.8 |
86.5 |
|
81.1 |
|
Cost of production, bln rub |
|
|
0.047 |
0.600 |
2.22 |
3.24 |
0.437 |
|
0.344 |
|
R&D, bln rub |
|
|
21.8 |
48.2 |
96.8 |
64.4 |
59.4 |
|
54.0 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.001 |
0.000 |
0.000 |
0.000 |
|
0.686 |
|
|
Assets, bln rub |
|
|
158.3 |
329.7 |
247.7 |
156.3 |
158.6 |
|
137.9 |
|
Net Assets, bln rub |
? |
|
-51.0 |
-118.2 |
-243.8 |
-335.0 |
116.7 |
|
97.4 |
|
Debt, bln rub |
|
|
200.6 |
8.74 |
28.5 |
28.1 |
25.3 |
|
19.7 |
|
Cash, bln rub |
|
|
154.7 |
315.1 |
209.8 |
122.8 |
131.4 |
|
112.7 |
|
Net debt, bln rub |
|
|
45.9 |
-306.3 |
-181.3 |
-94.7 |
-106.1 |
|
-93.0 |
|
|
Ordinary share price, rub |
|
|
|
32.1 |
5.33 |
1.80 |
2.81 |
|
1.80 |
|
Number of ordinary shares, mln |
|
|
35.9 |
32.9 |
36.2 |
36.3 |
44.0 |
|
56.5 |
|
|
Market cap, bln rub |
|
|
0 |
1 055 |
193 |
65 |
124 |
|
102 |
|
EV, bln rub |
? |
|
46 |
748 |
12 |
-29 |
17 |
|
9 |
|
Book value, bln rub |
|
|
-51 |
-118 |
-244 |
-335 |
117 |
|
97 |
|
|
EPS, rub |
? |
|
-1.15 |
-1.99 |
-3.40 |
-2.33 |
-1.88 |
|
-1.29 |
|
FCF/share, rub |
|
|
-0.69 |
-1.59 |
-2.84 |
-2.35 |
-1.52 |
|
-0.82 |
|
BV/share, rub |
|
|
-1.42 |
-3.59 |
-6.74 |
-9.22 |
2.66 |
|
1.72 |
|
|
EBITDA margin, % |
? |
|
|
|
|
|
|
|
-1 603% |
|
Net margin, % |
? |
|
|
|
|
|
|
|
-1 494% |
|
FCF yield, % |
? |
|
|
-4.96% |
-53.3% |
-130.4% |
-54.0% |
|
-45.7% |
|
ROE, % |
? |
|
80.7% |
55.4% |
50.5% |
25.2% |
-70.6% |
|
-75.0% |
|
ROA, % |
? |
|
-26.0% |
-19.9% |
-49.7% |
-54.1% |
-52.0% |
|
-53.0% |
|
|
P/E |
? |
|
0.00 |
-16.1 |
-1.57 |
-0.77 |
-1.50 |
|
-1.39 |
|
P/FCF |
|
|
0.00 |
-20.2 |
-1.88 |
-0.77 |
-1.85 |
|
-2.19 |
|
P/S |
? |
|
|
|
|
|
|
|
20.8 |
|
P/BV |
? |
|
0.00 |
-8.92 |
-0.79 |
-0.20 |
1.06 |
|
1.04 |
|
EV/EBITDA |
? |
|
-1.57 |
-11.2 |
-0.09 |
0.32 |
-0.20 |
|
-0.11 |
|
Debt/EBITDA |
|
|
-1.57 |
4.60 |
1.43 |
1.03 |
1.23 |
|
1.19 |
|
|
R&D/CAPEX, % |
|
|
103 586% |
33 950% |
3 573% |
33 561% |
179 848% |
|
183.3% |
|
|
CAPEX/Revenue, % |
|
|
|
|
|
|
|
|
602.5% |
|
| Black Diamond Therapeutics shareholders |
